¹ Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park, Swansea, UK, SA2 8PP

² Tritech Institute, Hywel Dda University Health Board, Llanelli, UK, SA14 9TD

³ Cardiology Dept., Hywel Dda University Health Board, Glangwili Hospital, Carmarthen, UK, SA31 2AF

⁴ Pharmacy Department, Hywel Dda University Health Board, Prince Phillip Hospital, Llanelli, UK, SA14 8QF

European clinical guidelines recommend that patients with atherosclerotic cardiovascular disease (ASCVD), including ischaemic heart disease (IHD), stroke and peripheral arterial disease (PAD), are prescribed lipid lowering treatment (LLT) and treated to target low-density lipoprotein cholesterol (LDL-C) levels. This study aimed to document trends in ASCVD including treatment, monitoring, and achievement of target LDL-C.

Daniel E Harris, Daniel King, Ashley Akbari, Mike Gravenor, Mathew Lawrence, Clive Weston, Chris Hopkins, Leighton Phillips, Julian Halcox, Trends in Atherosclerotic Cardiovascular Disease and lipid management. A population-level observational cohort study in Wales, European Journal of Preventive Cardiology, 2024; https://doi.org/10.1093/eurjpc/zwae233

This study was funded by an unrestricted research grant from Amgen.

This study makes use of anonymised data held in the Secure Anonymised Information Linkage (SAIL) Databank. We would like to acknowledge all the data providers who make anonymised data available for research.

All research has been completed under the permission and approval of the SAIL independent Information Governance Review Panel (IGRP) project number 1483. Further details of this process can be found on the SAIL Databank website (https://saildatabank.com/)

Shield:

This work is licensed under a Creative Commons Attribution 4.0 International License.